IBA Dosimetry introduces SciMoCa™, the next-generation Monte Carlo secondary dose check and plan QA solution

Monte Carlo accuracy can now be applied with clinical workflow simplicity as a secondary independent plan QA solution for all standard Linacs, TPS solutions and RT applications.

IBA Dosimetry Product SciMoCA

Nashville, TN, USA, July 30, 2018 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, launched SciMoCa, the new Monte Carlo-powered secondary dose check and plan verification software, at the 60th annual AAPM meeting.

Monte Carlo is generally accepted as the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, Monte Carlo accuracy is now available for secondary independent dose calculation and verification, allowing users to verify the most advanced treatment plans with an equally robust QA solution.

SciMoCa’s design and implementation have been optimized for clinical efficiency and workflow simplicity. Workflow integration and automation ensure seamless application of Monte Carlo QA for clinical needs, allowing patients of all major treatment modalities to benefit from Monte Carlo accuracy without the time-consuming operations of “academic” Monte Carlo solutions of the past. Comprehensive verification tools such as comparative DVH review, 3D gamma analysis and plan quality reporting enable fast and intuitive treatment plan QA.

“IBA has always strived to provide cutting edge QA solutions to improve cancer treatments and safety for radiation therapy patients. Introducing Monte Carlo plan QA seamlessly for all major Linacs, TPS systems and treatment modalities introduces an additional level of QA accuracy in our industry,” said Jean-Marc Bothy, President of IBA Dosimetry GmbH. “At this year’s AAPM in Nashville we received exceptionally positive feedback from the medical physics community about SciMoCa’s unprecedented Monte Carlo workflow automation, calculation speed and proven accuracy”.

SciMoCa is FDA-cleared and immediately available for clinical use in the U.S. to bring secondary 3D plan QA to a new level of accuracy for all major Linacs from Varian, Elekta and Siemens, including the Accuray CyberKnife®.

SciMoCa is a solution developed by Radialogica and Scientific RT. IBA has entered into a global distribution agreement with Radialogica for the SciMoCa Monte Carlo powered secondary plan calculation and verification software.

We are delighted to enter into this agreement with IBA Dosimetry for the global distribution of SciMoCa Monte Carlo plan QA,” said Andrew Cowen, Chief Executive Officer of Radialogica. “IBA Dosimetry has established a leading position in the field of radiation therapy integrated quality assurance with a strong and global distribution network. We look forward to partnering with IBA Dosimetry to bring this important technology to patients and providers around the world.”

“With the availability of this clinically proven Monte Carlo QA solution a new era of 3D patient QA has begun,” said Prof. Dr. Markus Alber, Head of Scientific RT and Monte Carlo expert. “Recent peer-reviewed publications have proven SciMoCa’s accuracy and calculation speed, which is the basis for efficient clinical implementation.”

To find out more about SciMoCa please visit: https://www.iba-dosimetry.com/product/scimocatm/

 

About IBA Dosimetry
IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.
Find more information at iba-dosimetry.com

 

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at iba-worldwide.com.

 

About Radialogica
Radialogica, a privately held business based in St. Louis, is a healthcare IT company focused on advanced software solutions for radiation. The company provides sophisticated software and robust analytics to elevate quality of care for cancer patients. Radialogica’s organizational strategy, capabilities and resources are unified around a deep commitment to quality and value in oncology, and the goal of reducing the physical and financial burden of cancer treatment and survivorship.

For more information visit radialogica.com.

 

About Scientific RT
Scientific RT, a privately held business based in Munich, is a healthcare consulting and IT company specializing in Medical Physics in Radiotherapy. The company´s mission is to develop best-in-class algorithms for radiation dose computation and optimization together with its clinical customers, academic research collaborators, and commercial partners. The company has successfully consulted virtually all major players in Radiotherapy.

For more information visit scientific-rt.com.

 

Media Contact:
Ralf Schira
Director Global Marketing, IBA Dosimetry, ralf.schira@iba-group.com

Andrew Cowen
Chief Executive Officer, Radialogica, andy@radialogica.com